Physician profile
Kyle Mock
NPI 1265876494
$2,045.35
in general payments reported to CMS, 2019-2025
18 companies · $392 in 2025
The $392 reported for 2025 was less than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $487 · 2020: $253 · 2021: $19.13 · 2022: $391 · 2023: $257 · 2024: $247 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $896.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $895.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $668.45 | 2019-2025 | |
| Medtronic, INC. | $534.07 | 2022-2025 | Interstim |
| Sumitomo Pharma America, INC. | $223.91 | 2023-2025 | Gemtesa, Orgovyx |
| Caldera Medical, INC | $128.36 | 2023-2025 | Desara |
| Medtronic USA, INC. | $108.26 | 2020 | |
| Axonics, INC. | $95.93 | 2020-2023 | Axonics, Bulkamid |
| Astellas Pharma US INC | $66.51 | 2022-2024 | Myrbetriq |
| Boston Scientific Corporation | $32.40 | 2019-2025 | Bulkamid |
| Gilead Sciences, INC. | $22.96 | 2025 | |
| Abbvie INC. | $22.21 | 2022 | |
| Urogen Pharma, INC. | $22.08 | 2023 | Jelmyto |
| Bluewind Medical | $19.96 | 2025 | Revi |
| Bayer Healthcare Pharmaceuticals INC. | $19.12 | 2023 | |
| Pacira Pharmaceuticals Incorporated | $18.50 | 2024 | Exparel |
| Dendreon Pharmaceuticals LLC | $17.53 | 2023 | Provenge |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $16.97 | 2024 | |
| Laborie Medical Technologies Corp. | $15.18 | 2023 | |
| Hollister Incorporated | $12.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Mock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.